LIBRAINFU Libra Infusions Ltd.
Pharmaceuticals & Chemicals
Tk 517.3 as of 2026-11-12 14:00:00
Rank 296 of all scored
Data completeness 100%
Data completeness 100%
Score breakdown
Consistency 58
Profitability 0
Solvency 87
Valuation 24
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Consistency Paid a dividend every year (5/5)
- Solvency Low debt: debt/equity 0.43x (below 0.5)
- Valuation Trades near book value (P/NAV 0.61x)
Concerns
- Consistency Net loss in 1 of the last 5 years
- Profitability Average ROE only -0.05% (below 10%: capital not working hard)
- Profitability Net profit shrinking 55.92% a year
- Valuation P/E 3448.67 is high (above 20)
- Valuation Price is 870% above the Graham fair value (Tk 53.3)
Notes
- Consistency EPS rose in 2 of 4 years (mixed)
Risk flags
- Category Z (poor/defaulting: gambling favourite, avoid for long-term)
- Small cap (< Tk 200 cr): most exposed to manipulation and volatility
- Thin trading (last day ~Tk 0.14 cr)
- Within 3.88% of its 52-week low: check WHY before treating it as cheap
Valuation
P/E
P/E audited
P/E current
P/B
NAV per share
EPS (last audited year)
Graham fair value
Margin of safety
52-week range
3.9% above the low, 30% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
ROE
ROE avg
ROE min
Profit CAGR
Profit YoY
Net profit
EPS up
Loss years (last ~5)
Dividends and safety
Div years
Dividend yield
Payout
Cash div
D/E
Loans/MCap
Size, liquidity and ownership
MCap
Free float
Daily turnover
Sponsor %
Inst. %
Public %
Foreign %
Shareholding
- Sponsor/director 34.4%
- Institution 4.2%
- Public 61.3%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2017 | 4.86 | 1,577.96 | 1 | 30 | 0 |
| 2018 | 5.01 | 1,593.47 | 1 | 0 | 20 |
| 2019 | 1.05 | 1,269 | 0 | 5 | 0 |
| 2020 | -7.78 | 1,261 | -1 | 5 | 0 |
| 2021 | 0.15 | 1,261 | 0 | 30 | 50 |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 70.4%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.